



## Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

03-27-2024 at 10:23 AM EDT

*Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium*

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company will present four scientific posters at the upcoming 2024 American Thoracic Society (ATS) International Conference, taking place in San Diego, California from May 17-22, 2024.

The following abstracts are posted on ATS 2024's online itinerary planner.

**Title:** [Post-hoc Analysis of Biomarkers of Interstitial Lung Disease Progression in Participants with Idiopathic Pulmonary Fibrosis Receiving Bexotegrast Over 12-weeks in INTEGRIS-IPF](#)

**Presenter:** Martin L. Decaris, Ph.D., Senior Director, Translational Sciences, Pliant Therapeutics

**Poster:** 15055

**Session A68:** Unveiling Novel Avenues in IPF Therapies

**Date:** Sunday, May 19, 2024

**Presentation Time:** 11:30 a.m. – 1:15 p.m. Pacific Time

**Location:** TDP15

**Title:** [Bexotegrast Targets TGF-beta Inhibition to Specific Cell Types in the Fibrotic Human Lung](#)

**Presenter:** Mahru C. An, Ph.D., Principal Scientist, Pliant Therapeutics

**Poster:** 11411

**Session B29:** Biomarkers and New Therapeutics Targets in Lung Fibrosis

**Date:** Monday, May 20, 2024

**Presentation Time:** 9:15 a.m. – 11:15 a.m. Pacific Time

**Location:** San Diego Convention Center, Room 30C-E (Upper Level)

**Title:** [Evaluation of Quantitative Imaging in a Phase 2a Study for the Treatment of Idiopathic Pulmonary Fibrosis with Bexotegrast \(INTEGRIS-IPF\)](#)

**Presenter:** Jonathan G. Goldin, M.D., Ph.D., Professor of Radiology, Medicine and Biomedical Physics at the David Geffen School of Medicine at the University of California, Los Angeles

**Poster:** 10368

**Session C23:** Machine Learned: AI-Driven Solutions in ILD and Lung Transplant

**Date:** Tuesday, May 21, 2024

**Presentation Time:** 9:15 a.m. – 11:15 a.m. Pacific Time

**Location:** San Diego Convention Center, Room 33A-C (Upper Level)

Pliant was also selected for a featured oral presentation as part of the ATS 2024 Mini Symposiums program.

**Title:** [Update on the Safety and Tolerability of Bexotegrast, A Dual-selective Inhibitor of Integrins  \$\alpha v\beta 6\$  and  \$\alpha v\beta 1\$ , in Development for Idiopathic Pulmonary Fibrosis and Primary Sclerosing Cholangitis](#)

**Presenter:** Gregory P. Cosgrove, M.D., FCCP, Vice President, Clinical Development, Pliant Therapeutics

**Oral Presentation:** 10340

**Mini Symposium C95:** New Clinical Trial Results in Chronic Lung Disease

**Date:** Tuesday, May 21, 2024

**Presentation Time:** 3:51 p.m. – 4:03 p.m. Pacific Time

**Location:** San Diego Convention Center, Ballroom 20A (Upper Level)

Posters will be available to view during the ATS Conference, Sunday, May 19 - Wednesday, May 22.

### About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of  $\alpha v\beta 6$  and  $\alpha v\beta 1$  integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant is conducting BEACON-IPF, a Phase 2b/3 trial of bexotegrast in IPF. Pliant has also developed PLN-1474, a small molecule, selective inhibitor of  $\alpha v\beta 1$  integrin for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH. Pliant has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of  $\alpha v\beta 8$  and  $\alpha v\beta 1$  integrins, that is being developed for the treatment of solid tumors. In addition to clinical-stage programs, Pliant currently has a preclinical program targeting muscular dystrophies. For additional information, please visit: [www.PliantRx.com](http://www.PliantRx.com). Follow us on

social media: [X](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

**Investor and Media Contact:**

Christopher Keenan  
Vice President, Investor Relations and Corporate Communications  
Pliant Therapeutics, Inc.  
[ir@pliantrx.com](mailto:ir@pliantrx.com)